10-K/A: TG Therapeutics Amends 10-K Filing Due to Material Weakness in Internal Controls Over Share-Based Payment Awards

TG Therapeutics is amending its annual report on Form 10-K for the fiscal year ended December 31, 2023, to address a material weakness identified in its internal control over financial reporting related to share-based payment awards.

Summary

• TG Therapeutics is filing an amendment to its annual report on Form 10-K for the year ended December 31, 2023.
• The amendment addresses a material weakness identified in the company's internal control over financial reporting (ICFR).
• The material weakness relates to the expense recognition of a restricted stock grant in 2021, leading to an understatement of non-cash compensation expense for 2021 and 2022.
• Management reassessed the effectiveness of the company's ICFR as of December 31, 2023, and concluded that the error was caused by an underlying control deficiency related to non-routine share-based payment awards.
• KPMG LLP, the company's independent registered public accounting firm, has amended its audit reports to reflect the material weakness.
• The company is implementing enhanced risk assessment procedures and additional preventative controls to remediate the material weakness.
• Management anticipates that the material weakness will be fully remediated before December 31, 2024.
• The original Form 10-K was filed with the SEC on February 29, 2024.
• The company's common stock is traded on the NASDAQ Capital Market under the symbol TGTX.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the identification of a material weakness in internal controls, but the company is taking steps to remediate the issue, which provides some reassurance.

Positives

• The company is taking steps to remediate the identified material weakness in its internal control over financial reporting.
• Management is committed to implementing enhanced risk assessment procedures and additional preventative controls.
• The company anticipates that the material weakness will be fully remediated before December 31, 2024.
• The company's management believes that the consolidated financial statements included in the Original Form 10-K fairly present the company's financial position, results of operations, and cash flows as of and for the periods presented, in accordance with U.S. GAAP.

Negatives

• A material weakness has been identified in the company's internal control over financial reporting related to share-based payment awards.
• KPMG has issued an adverse opinion on the effectiveness of the company's internal control over financial reporting as of December 31, 2023.
• The company's disclosure controls and procedures were not effective as of December 31, 2023, due to the material weakness in internal control over financial reporting.

Risks

• The material weakness in internal control over financial reporting could lead to potential misstatements in the company's financial statements.
• Failure to fully remediate the material weakness could result in further adverse opinions from the company's independent registered public accounting firm.
• The company's disclosure controls and procedures were not effective as of December 31, 2023, due to the material weakness in internal control over financial reporting.
• There is a risk that the updated policies and training may not be in place and operated for a sufficient period of time to enable management and KPMG LLP to test and to conclude on the operating effectiveness of the controls.

Future Outlook

The company anticipates that the material weakness will be fully remediated before December 31, 2024, after updated policies and training have been in place and operated for a sufficient period of time.

Management Comments

• Management believes that the consolidated financial statements included in the Original Form 10-K fairly present the company's financial position, results of operations, and cash flows as of and for the periods presented, in accordance with U.S. GAAP.

Industry Context

The identification and remediation of material weaknesses in internal controls are a standard part of financial reporting for publicly traded companies, ensuring compliance with regulatory requirements and maintaining investor confidence.

Comparison to Industry Standards

• Many pharmaceutical companies, such as Amgen, Biogen, and Gilead Sciences, are subject to rigorous internal control assessments and audits to ensure compliance with Sarbanes-Oxley Act requirements.
• The identification of a material weakness is not uncommon, and companies are expected to implement remediation plans to address the deficiencies.
• The remediation timeline provided by TG Therapeutics, aiming for completion before December 31, 2024, is a typical timeframe for addressing such issues.

Stakeholder Impact

• Shareholders may be concerned about the material weakness in internal controls and its potential impact on the accuracy of financial reporting.
• Employees involved in financial reporting may need to implement new procedures and controls to address the material weakness.
• The company's reputation may be negatively impacted by the disclosure of the material weakness.

Next Steps

• The company will implement enhanced risk assessment procedures to ensure that all non-routine share-based payment awards are appropriately identified and evaluated.
• The company will design additional preventative controls around non-routine share-based payment awards to ensure the appropriate recognition and measurement of such awards.
• Management will report regularly to the audit committee on the progress and results of the remediation plan, including the identification, status, and resolution of internal control deficiencies.
• KPMG LLP will test and conclude on the operating effectiveness of the controls.

Key Dates

Keywords

internal control, material weakness, financial reporting, share-based payment, Form 10-K/A, TG Therapeutics, KPMG, audit, remediation, disclosure controls, ICFR